Population
Patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
Design
Review
Key result
Various therapeutic modalities for NAFLD and NASH have shown initial promise, but none have established long-term efficacy in randomized clinical trials.
Authors
Loading...
No NAFLD/NASH therapy should alter practice yet; leaves open the need for definitive long-term RCTs.
This review highlights that while various treatments for NAFLD/NASH show initial promise, none have established long-term efficacy in randomized clinical trials.
Lam et al. (2010) conducted a review in Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Various therapeutic modalities (weight loss agents, bariatric surgery, pharmacologic agents) was evaluated. Various therapeutic modalities for NAFLD and NASH have shown initial promise, but none have established long-term efficacy in randomized clinical trials.